SEARCH

SEARCH BY CITATION

References

  • Beck, J., Handgretinger, R., Dopfer, R., Klingebiel, T., Niethammer, D. & Gekeler, V. (1995) Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. British Journal of Haematology, 89, 356363.
  • Beck, J., Handgretinger, R., Klingebiel, T., Dopfer, R., Schaich, M., Ehninger, G., Niethammer, D. & Gekeler, V. (1996) Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia, 10, 426433.
  • Borg, A.G., Burgess, R., Green, L.M., Scheper, R.J. & Yin, J.A. (1998) Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. British Journal of Haematology, 103, 10831091.
  • Borg, A.G., Burgess, R., Green, L.M., Scheper, R.J. & Liu Yin, J.A. (2000) P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells. British Journal of Haematology, 108, 4854.
  • Byrd, J.C., Mrozek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A. & Bloomfield, C.D. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, 43254336.
  • Clark, J.M. (1988) Novel non-templated nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases. Nucleic Acids Research, 16, 96779686.
  • Filipits, M., Suchomel, R.W., Zochbauer, S., Brunner, R., Lechner,K. & Pirker, R. (1997) Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clinical Cancer Research, 3, 14191425.
  • Filipits, M., Pohl, G., Stranzl, T., Suchomel, R.W., Scheper, R.J., Jager, U., Geissler, K., Lechner, K. & Pirker, R. (1998) Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood, 91, 15081513.
  • Galimberti, S., Testi, R., Guerrini, F., Fazzi, R. & Petrini, M. (2003a) The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. Journal of Chemotherapy, 15, 374379.
  • Galimberti, S., Rossi, A., Palumbo, G.A., Morabito, F., Guerrini, F., Vincelli, I., Fazzi, R., Santini, V. & Petrini, M. (2003b) FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia. Anticancer Research, 23, 34193426.
  • Gramatzki, M., Ludwig, W.D., Burger, R., Moos, P., Rohwer, P., Grunert, C., Sendler, A., Kalden, J.R., Andreesen, R., Henschke, F. & Moldenhauer, G. (1998) Antibodies TC-12 (‘‘unique’’) and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Experimental Hematology, 26, 12091214.
  • Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 23222333.
  • van den Heuvel-Eibrink MM., van der, H.B., te Boekhorst, P.A., Pieters, R., Schoester, M., Lowenberg, B. & Sonneveld, P. (1997) MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. British Journal of Haematology, 99, 7683.
  • Hunault, M., Zhou, D., Delmer, A., Ramond, S., Viguie, F., Cadiou, M., Perrot, J.Y., Levy, V., Rio, B., Cymbalista, F., Zittoun, R. & Marie, J.P. (1997) Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Annals of Hematology, 74, 6571.
  • Izquierdo, M.A., Shoemaker, R.H., Flens, M.J., Scheffer, G.L., Wu, L., Prather, T.R. & Scheper, R.J. (1996) Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. International Journal of Cancer, 65, 230237.
  • Kern, W., Haferlach, T., Schoch, C., Loffler, H., Gassmann, W., Heinecke, A., Sauerland, M.C., Berdel, W., Buchner, T. & Hiddemann, W. (2003) Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood, 101, 6470.
  • Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., Akiyama, H., Saito, K., Oh, H., Motoji, T., Omoto, E., Saito, H., Ohno, R. & Ueda, R. (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood, 93, 30743080.
  • van der Kolk, D.M., de Vries, E.G., Noordhoek, L., van den, B.E., van der Pol, M.A., Muller, M. & Vellenga, E. (2001) Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia, 15, 15441553.
  • Koo, H.M., Gray-Goodrich, M., Kohlhagen, G., McWilliams, M.J., Jeffers, M., Vaigro-Wolff, A., Alvord, W.G., Monks, A., Paull, K.D., Pommier, Y. & Vande Woude, G.F. (1999) The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. Journal of the National Cancer Institute, 91, 236244.
  • Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 17521759.
  • Lamy, T., Goasguen, J.E., Mordelet, E., Grulois, I., Dauriac, C., Drenou, B., Chaperon, J., Fauchet, R. & le Prise, P.Y. (1994) P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia, 8, 18791883.
  • Laupeze, B., Amiot, L., Drenou, B., Bernard, M., Branger, B., Grosset, J.M., Lamy, T., Fauchet, R. & Fardel, O. (2002) High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. British Journal of Haematology, 116, 834838.
  • Lautier, D., Canitrot, Y., Deeley, R.G. & Cole, S.P. (1996) Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochemistry and Pharmacology, 52, 967977.
  • Legrand, O., Simonin, G., Zittoun, R. & Marie, J.P. (1998) Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia, 12, 13671374.
  • Legrand, O., Zittoun, R. & Marie, J.P. (1999) Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia, 13, 578584.
  • Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum, F.R. & Willman, C.L. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 33233329.
  • Leith, C.P., Kopecky, K.J., Chen, I.M., Eijdems, L., Slovak, M.L., McConnell, T.S., Head, D.R., Weick, J., Grever, M.R., Appelbaum, F.R. & Willman, C.L. (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 94, 10861099.
  • List, A.F. (1996) Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia, 10, 937942.
  • Michieli, M., Damiani, D., Ermacora, A., Raspadori, D., Michelutti, A., Grimaz, S., Fanin, R., Russo, D., Lauria, F., Masolini, P. & Baccarani, M. (1997) P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. British Journal of Haematology, 96, 356365.
  • Mohr, B., Bornhauser, M., Thiede, C., Schakel, U., Schaich, M., Illmer, T., Pascheberg, U. & Ehninger, G. (2000) Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia, 14, 10311038.
  • Norgaard, J.M., Bukh, A., Langkjer, S.T., Clausen, N., Palshof, T. & Hokland, P. (1998) MDR1 gene expression and drug resistance of AML cells. British Journal of Haematology, 100, 534540.
  • Pallis, M., Turzanski, J., Grundy, M., Seedhouse, C. & Russell, N. (2003) Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications. British Journal of Haematology, 120, 10091016.
  • Raaijmakers, H.G., Izquierdo, M.A., Lokhorst, H.M., de Leeuw, C., Belien, J.A., Bloem, A.C., Dekker, A.W., Scheper, R.J. & Sonneveld, P. (1998) Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood, 91, 10291036.
  • Samdani, A., Vijapurkar, U., Grimm, M.A., Spier, C.S., Grogan, T.M., Glinsmann-Gibson, B.J. & List, A.F. (1996) Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leukemia Research, 20, 175180.
  • Schaich, M., Ritter, M., Illmer, T., Lisske, P., Thiede, C., Schakel, U., Mohr, B., Ehninger, G. & Neubauer, A. (2001) Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. British Journal of Haematology, 112, 300307.
  • Schaich, M., Harbich-Brutscher, E., Pascheberg, U., Mohr, B., Soucek, S., Ehninger, G. & Illmer, T. (2002) Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica, 87, 455464.
  • Simon, S.M. & Schindler, M. (1994) Cell biological mechanisms of multidrug resistance in tumors. Proceedings of the National Academy of Sciences of the United States of America, 91, 34973504.
  • Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 96, 40754083.
  • Smeets, M.E., Raymakers, R.A., Vierwinden, G., Pennings, A.H., Wessels, H. & de Witte, T. (1999) Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance. Blood, 94, 24142423.
  • Sunnaram, B.L., Gandemer, V., Sebillot, M., Grandgirard, N., Amiot, L., Leray, E. & Goasguen, J.E. (2003) LRP overexpression in monocytic lineage. Leukemia Research, 27, 755759.
  • Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 43264335.
  • Tsimberidou, A.M., Paterakis, G., Androutsos, G., Anagnostopoulos, N., Galanopoulos, A., Kalmantis, T., Meletis, J., Rombos, Y., Sagriotis, A., Symeonidis, A., Tiniakou, M., Zoumbos, N. & Yataganas, X. (2002) Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leukemia Research, 26, 143154.
  • Walter, R.B., Raden, B.W., Hong, T.C., Flowers, D.A., Bernstein, I.D. & Linenberger, M.L. (2003) Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood, 102, 14661473.
  • Wiemer, E., Schoester, M. & Sonneveld, P. (1998) Intracellular localization and dynamics of the vault complex in non-Pgp multidrug resistant cell lines. Blood, 92, 676a.
  • Willman, C.L. (1999) Molecular evaluation of acute myeloid leukemias. Seminars in Hematology, 36, 390400.
  • Wuchter, C., Karawajew, L., Ruppert, V., Buchner, T., Schoch, C., Haferlach, T., Ratei, R., Dorken, B. & Ludwig, W.D. (1999) Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia, 13, 19431953.